Ph.d.-stilling i translationel kræftforskning – Kombination af antistof-lægemiddel-konjugater og stråleterapi

This Ph.D. position in translational cancer research focuses on the combination of antibody-drug conjugates (ADCs) and radiotherapy. The role requires a solid understanding of cancer biology, molecular oncology, and the mechanisms of action of targeted therapies such as ADCs. Candidates should have experience or strong knowledge in preclinical research methods, including in vitro and in vivo models to study therapeutic efficacy and safety. Familiarity with radiobiology principles and radiation treatment modalities is essential to explore synergistic effects between ADCs and radiotherapy. The position demands skills in experimental design, data analysis, and interpretation within a translational research framework aimed at bridging laboratory findings to clinical applications. A mid-level experience suggests prior involvement in cancer research projects, possibly including molecular techniques such as immunohistochemistry, flow cytometry, and pharmacokinetic/pharmacodynamic assessments. The candidate should be proficient in scientific communication, capable of contributing to publications and presentations. Collaborative work within multidisciplinary teams combining oncology, pharmacology, and radiation therapy expertise is expected. Overall, the role suits a researcher with a strong foundation in cancer therapeutics development, translational research methodologies, and an interest in innovative combination treatments to improve cancer patient outcomes.